



*NEWS RELEASE*

FOR IMMEDIATE RELEASE

Contact: Ronald C. Trahan, APR, President, Ronald Trahan Associates Inc., +1-508-816-6730

## **First patient enrolled in randomized study of Stentys *self-expanding* stent vs. conventional stent to treat acute myocardial infarction (AMI)**

### **‘APPOSITION II’ study to compare stent apposition and adaptation to vessel growth**

PRINCETON, N.J., and PARIS, Dec. 4, 2009—Medical device pioneer **Stentys** announced today that the first patient has been enrolled into the ‘**APPOSITION II**’ clinical study—a randomized trial comparing the Stentys *self-expanding* stent with a conventional balloon-expandable stent in AMI patients. The primary endpoint of the ‘**APPOSITION II**’ study is stent strut apposition at day three post-procedure via extremely high-resolution OCT (optical coherence tomography) imaging.

“The first **APPOSITION II** case went extremely well,” said **Prof. Christian Spaulding, M.D., Ph.D.**, chief of interventional cardiology at Cochin Hospital, Descartes University, Paris. “Three days later, thrombus and spasm had resolved, and the stent was perfectly apposed under OCT. This represents a breakthrough for successfully treating AMI.”

“We have already demonstrated how the Stentys stent adapts perfectly to the changing vessel anatomy following AMI stenting. We are convinced that the **APPOSITION II** study will further validate its superiority over existing stents to treat AMI patients,” said **Gonzague Issenmann, CEO and co-founder of Stentys**, “and thereby substantiate that *all* AMI patients should be treated with our self-expanding technology.”

The *self-expanding* feature of the Stentys platform, unrivaled in the stent industry, is designed to insure optimal apposition of a stent in the critical initial hours and days after an AMI procedure, by being continuously applied to the vessel’s internal surface even during thrombus and vessel spasm relief—thereby avoiding *malapposition*, a significant concern to cardiologists.

#### **About Stentys**

Based in Princeton, N.J., and Paris, [Stentys](#) intends to make treatment of complex blocked coronary arteries as simple and effective as a conventional stenting procedure. Stentys was co-founded by [Gonzague Issenmann](#) and [Jacques Séguin, M.D., Ph.D., founder of CoreValve](#), which was acquired this year by **Medtronic for \$700 million plus earn-outs**.

#####